With AI-BIO
PIPELINE
Pipeline
Baobab AiBIO Pipeline
Drug Repositioning
New Chemical Entity
Large Molecule
Status | Program | Target Disease | Exploratory | Research | IND Enabling | Early Clinical | Late Clinical | Milestone/Issue |
---|---|---|---|---|---|---|---|---|
Active | BAB-104 | MSTO, GBM | ![]() |
IND in 4Q 2023 | ||||
BAB-107 | mCRC | ![]() |
in Vivo tool 4Q 2022 | |||||
BAB-201 | Fibrosis | ![]() |
Collaboration | |||||
BAB-202 | RA | ![]() |
Collaboration | |||||
BAB-301 | Parkinson | ![]() |
Hit 2Q 2022 | |||||
BAB-802 | Antibody | ![]() |
Collaboration | |||||
BAB-803 | Fibrosis | ![]() |
Collaboration | |||||
Basic Study |
BAB-103 | CRC, NSCLC | ![]() |
Properties improvement | ||||
BAB-105 | Breast Cancer | ![]() |
Collaboration | |||||
BAB-106 | Cancer metastasis | ![]() |
Collaboration | |||||
Undisclosed | immuno Oncology | ![]() |
structure 1Q 2022 | |||||
Undisclosed | Fibrosis | ![]() |
structure 2Q 2022 |